AMSilk and Fraunhofer Institute for Applied Polymer Research Join in the Development of New Spin Process for Spider Silk
AMSilk and the Fraunhofer Institute for Applied Polymer Research (IAP) join forces in the current development of a novel spin process for making high performance fibers from AMSilk’s spider silk proteins. AMSilk is the first company able to deliver sufficient spider silk material for applications development. AMSilk’s spider silk is inspired by the natural silk from spiders and produced through biotechnology with an industrial production platform. To date, no industrial spinning process has delivered a fiber that can be compared to natural spider silk as found in a spider web. The present collaboration will match AMSilk’s material and biochemical expertise with Fraunhofer’s expertise in developing spin processes for biopolymers. The partners expect to deliver a new process for making artificial spider silk fibers for high tech applications.
“Having Fraunhofer-Gesellschaft, one of the world’s most renowned research institutions, as our partner in this exciting project, is a great advantage for AMSilk,” says Axel Leimer, AMSilk CEO. “We fit perfectly together, both in expertise and vision.”
“We are very proud to be involved in the development of a new generation of high performance protein fibers. In a unique way we will combine synthetic spider silk from AMSilk and biopolymer spinning technology from Fraunhofer IAP”, says Prof. Dr. Hans-Peter Fink, the director of Fraunhofer IAP.
The development collaboration will run over at least two years. AMSilk will own commercial rights of the results with certain benefits for Fraunhofer IAP.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Lumiphore, Inc. - Richmond, USA

Lactate for Brain Energy
List_of_bolete_species
CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
Casting a wide net to fight coronaviruses
Sexual transmission of Ebola likely to impact course of outbreaks
How a protein in your brain could protect against Alzheimer's disease - New research sets the stage for new therapeutic strategies for Alzheimer's disease
New model finds HIV acute phase infectivity may be lower than previously estimated

KNAUER is expanding its business activities into the field of lipid nanoparticle production equipment - In connection with the development of mRNA-based vaccines against Corona, LNPs have shown to be a suitable delivery form
